Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportOncology, Clinical Diagnosis Track

Early initiation of Lu-177 PSMA radioligand therapy prolongs overall survival in metastatic prostate cancer

Harshad Kulkarni, Christiane Schuchardt, AVIRAL SINGH, Thomas Langbein and Richard Baum
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 529;
Harshad Kulkarni
1THERANOSTICS Center for Molecular Radiotherapy Zentralklinik Bad Berka Bad Berka Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christiane Schuchardt
1THERANOSTICS Center for Molecular Radiotherapy Zentralklinik Bad Berka Bad Berka Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AVIRAL SINGH
1THERANOSTICS Center for Molecular Radiotherapy Zentralklinik Bad Berka Bad Berka Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Langbein
1THERANOSTICS Center for Molecular Radiotherapy Zentralklinik Bad Berka Bad Berka Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Baum
1THERANOSTICS Center for Molecular Radiotherapy Zentralklinik Bad Berka Bad Berka Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 59 no. supplement 1 529

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online May 23, 2018.

Copyright & Usage 
© 2018

Author Information

  1. Harshad Kulkarni1,
  2. Christiane Schuchardt1,
  3. AVIRAL SINGH1,
  4. Thomas Langbein1 and
  5. Richard Baum1
  1. 1THERANOSTICS Center for Molecular Radiotherapy Zentralklinik Bad Berka Bad Berka Germany

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: May 2018 to May 2023

AbstractFullPdf
May 2018500
Jun 201820200
Jul 201831800
Aug 20189300
Sep 201834600
Oct 201859800
Nov 201842700
Dec 201861500
Jan 201976700
Feb 201954100
Mar 201954300
Apr 201936200
May 201940700
Jun 201940500
Jul 201951700
Aug 201942200
Sep 201930100
Oct 201915400
Nov 201911200
Dec 20197800
Jan 20207400
Feb 202013800
Mar 202012300
Apr 20208800
May 20204300
Jun 20203200
Jul 20201900
Aug 20202100
Sep 20205700
Oct 20205700
Nov 20205200
Dec 20206300
Jan 20217700
Feb 202110800
Mar 202112700
Apr 202113400
May 20217200
Jun 20218100
Jul 202111400
Aug 20218600
Sep 20217500
Oct 20214600
Nov 20218200
Dec 20216900
Jan 202213100
Feb 20224800
Mar 20225200
Apr 20227600
May 20228100
Jun 20223700
Jul 202215100
Aug 20223700
Sep 20224500
Oct 20225900
Nov 20226900
Dec 20225000
Jan 202313100
Feb 20235700
Mar 20236800
Apr 20234000
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 59, Issue supplement 1
May 1, 2018
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Early initiation of Lu-177 PSMA radioligand therapy prolongs overall survival in metastatic prostate cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Early initiation of Lu-177 PSMA radioligand therapy prolongs overall survival in metastatic prostate cancer
Harshad Kulkarni, Christiane Schuchardt, AVIRAL SINGH, Thomas Langbein, Richard Baum
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 529;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Early initiation of Lu-177 PSMA radioligand therapy prolongs overall survival in metastatic prostate cancer
Harshad Kulkarni, Christiane Schuchardt, AVIRAL SINGH, Thomas Langbein, Richard Baum
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 529;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • Combination Strategies to Improve Targeted Radionuclide Therapy
  • Google Scholar

More in this TOC Section

Oncology, Clinical Diagnosis Track

  • Immunohistochemical analysis of Gastrin-Releasing-Peptide receptor (GRPr) and Prostate-Specific- Membrane Antigen (PSMA) in primary prostate cancer: comparison with radiolabeled GRPr antagonist (68Ga-RM2) PET/CT
  • Relationship between FDG PETCT imaging and CA 125 levels in treated patients with Ovarian cancers - Can FDG PETCT define and predict the disease burden in clinically suspected recurrence ?
  • Cancer-associated fibroblasts enhance tumor 18F-FDG uptake and contribute to the intratumor heterogeneity of SUVmax
Show more Oncology, Clinical Diagnosis Track

Prostate: Therapy

  • Discrete evaluation of multi-cycle Lu-177-PSMA-617-therapy effects on bone versus lymph node metastases in patients with metastasized castration‑resistant prostate cancer (mCRPC)
  • Initial experience with 225Ac-PSMA-617 in patients with advanced-stage prostate cancer
  • Targeted Alpha Therapy of mCRPC with 225Actinium-PSMA617: Dosimetry, toxicity and duration of tumor-control.
Show more Prostate: Therapy

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire